SecBot SecBot
8-K ·Filed May 7, 2026

HAE

HAEMONETICS CORP
NEUTRAL
Impact 4/10
Horizondays Processed6mo ago SEC0000313143-26-000031
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The impairment masks a solid operational quarter. Focus on organic growth acceleration (4.5%) and FY2027 guidance implying mid-single-digit revenue growth and margin expansion. Watch for integration updates on Attune Medical and Vivasure on the earnings call.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$54.37
T+0 close · May 7, 2026 · via day close
Latest settled
+59.63%
T+60 · $86.79
Vs SPY
+55.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $54.37entry
  2. T+1 · 6mo ago +1.38%α +0.55% · $55.12
  3. T+5 · 6mo ago +4.86%α +3.35% · $57.01
  4. T+20 · 6mo ago +21.17%α +18.03% · $65.88
  5. T+60 · 4mo ago +59.63%α +55.80% · $86.79

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Haemonetics Q4 FY2026 revenue grew 4.8% YoY to $346.4M, beating estimates, while adjusted EPS of $1.29 edged past consensus. GAAP net loss of $20.1M was driven by a $77.2M impairment of intangible assets from the Attune Medical acquisition. FY2027 guidance calls for 4-7% reported revenue growth and 50-100bps adjusted operating margin expansion, signaling underlying business momentum.

Key Financial Metrics

EPS
$1.29
est $1.28 · +0.8%
Revenue
$346.4M
+4.8% YoY
Rating
beat
Guidance
4-7% reported growth
initiated
Free Cash Flow
$44.5M
Gross Margin
57.2%

Key Facts

  • Q4 revenue $346.4M, +4.8% YoY; organic revenue growth 4.5%; organic ex-CSL growth 8.6%
  • Q4 GAAP EPS -$0.44 (net loss $20.1M) vs $1.17 in prior year, due to $77.2M impairment charge
  • Q4 adjusted EPS $1.29, up 4.0% YoY; adjusted net income $59.7M, down 3.0%
  • FY2026 full year revenue $1.334B, -2.0% YoY; adjusted EPS $4.96, +8.5%
  • FY2027 guidance: reported revenue growth 4-7%, organic revenue growth 3-6%, adjusted operating margin expansion 50-100bps
  • Repurchased $100M in shares in Q4; $325M remaining under $500M authorization

Financial Impact

Non-cash impairment of $77.2M drove GAAP loss; adjusted operations remained profitable with $84.5M adjusted operating income.

gaap net incomeoperating incomefree cash flow

Risk Factors

  • Integration challenges from Attune Medical and Vivasure acquisitions
  • Interventional Technologies segment declined 10.3% organic in Q4
  • Tariff impacts on adjusted gross margin

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
67% bullish (15 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000313143-26-000031
Document: hae-20260507.htm0000313143-26-000031
Document: 0000313143-26-000031-index-headers.html0000313143-26-000031
Document: 0000313143-26-000031-index.html0000313143-26-000031
Document: 0000313143-26-000031.txt0000313143-26-000031
8-K Data (Synthetic)0000313143-26-000031

Track record

14 reports on HAE

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +2.44% at T+5 after the Oct 20, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 144 Neutral 2/10 Entry $122.71 Now $121.34 −1.12% settles Nov 19
  2. Nov 5, 202611d ago 8-K Bullish 6/10 No price data
  3. Nov 5, 202611d ago Press Release Bullish 5/10 Entry $124.11 to $122.71 Now $121.34 −2.23% ▼ −1.13% −4.42% vs SPY
  4. Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $117.11 to $119.97 Now $121.34 +3.61% ▲ +2.44% +2.89% vs SPY
  5. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $118.21 to $119.97 Now $121.34 +2.65% ▲ +1.49% +1.41% vs SPY
  6. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $122.06 to $118.73 Now $121.34 −0.59% ▼ −2.73% −1.23% vs SPY
  7. Oct 8, 20265w ago 8-K Neutral 4/10 Entry $119.47 to $121.29 Now $121.34 +1.57% ▲ +1.52% +1.80% vs SPY
  8. Sep 30, 20266w ago Press Release Neutral 1/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
  9. Sep 30, 20266w ago Court Ruling Neutral 3/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
  10. Aug 18, 202612w ago 8-K Neutral 3/10 Entry $104.65 to $108.32 Now $121.34 +15.95% ▲ +3.51% +3.71% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (11h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026